Skip to main content

Table 1 (abstract P384). Assessment of Disease Activity

From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)

Endpoint

BL (n=354)

3 mths (n=286)

6 mths (n=252)

1 yr (n=231)

2 yrs (n=81)

3 yrs (n=27)

3.5 yrs (n=14)

Physician Global Assessment of Disease Activity*3

2.0 (0.1)

1.5 (0.1)

1.5 (0.1)

1.2 (0.1)

0.8 (0.1)

1.2 (0.3)

1.1 (0.4)

Clinical inactive disease (Wallace criteria), %3,4

33

32

38

48

52

37

29

Joint assessment

3.1 (0.4)

2.7 (0.4)

2.8 (0.4)

2.1 (0.4)

1.1 (0.3)

1.9 (1.0)

2.1 (0.9)

Tenderness/pain

       

On motion

2.9 (0.3)

      

Active

 

2.0 (0.3)

2.2 (0.3)

1.8 (0.3)

1.2 (0.4)

3.0 (1.2)

2.6 (1.2)

JAMAR functional†

       

Child3

5.4 (0.4)

4.7 (0.4)

4.1 (0.4)

4.1 (0.4)

3.0 (0.5)

3.5 (0.9)

4.6 (1.5)

Parent

7.2 (0.7)

5.7 (0.5)

4.4 (0.4)

4.9 (0.9)

2.9 (0.5)

4.1 (1.2)

5.3 (1.8)

JAMAR HRQoL‡

       

Child3

7.0 (0.3)

6.0 (0.4)

5.5 (0.3)

5.1 (0.4)

4.5 (0.6)

6.5 (1.1)

7.0 (1.5)

Parent

8.3 (0.7)

7.0 (0.6)

6.8 (0.7)

6.3 (0.9)

6.4 (1.7)

4.4 (1.1)

7.1 (2.9)

  1. Data are mean (SE), unless otherwise indicated
  2. *Visual analogue scale 0–10; 0=inactive; †range 0–15, 0=no functional limitation; ‡range 0–15, 0=best possible HRQoL
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096